Takeda Pharmaceutical Management

Management Kriterienprüfungen 2/4

Takeda Pharmaceutical CEO ist Julie Kim , ernannt in Jun 2026, hat eine Amtszeit von weniger als ein Jahr. besitzt direkt 0.006% der Aktien des Unternehmens, im Wert von $2.89M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.3 Jahre bzw. 3.1 Jahre.

Wichtige Informationen

Julie Kim

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	0.005%
Durchschnittliche Amtszeit des Managements	3.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.1yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Julie Kim (56 yo)

less than a year

Amtszeit

Ms. So-Young Kim, also known as Julie, is CEO, President & Director of Takeda Pharmaceutical Company Limited from June 24, 2026. She joined the Takeda Pharmaceutical Company Limited in January 2019. She wa...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Milano Furuta	CFO & Director	2.3yrs	JP¥384.00m	0.0019% $ 1.0m
Andrew S. Plump	President of Research & Development and Representative Director	no data	JP¥1.26b	0.020% $ 10.4m
So-Young Kim	CEO, President & Director	less than a year	keine Daten	0.0055% $ 2.9m
Seigo Izumo	Chair of Management Board	no data	keine Daten	keine Daten
Haruhiko Hirate	Member of Management Board	no data	keine Daten	keine Daten
Salvatore Alesci	Member of Management Board and Head of R&D Global Science & Biomedical Policy	no data	keine Daten	keine Daten
Michael Fox	Chief Operating Officer	no data	keine Daten	keine Daten
Norimasa Takeda	Chief Accounting Officer & Corporate Controller	no data	keine Daten	keine Daten
Iwaaki Taniguchi	Senior Vice President of Corporate Finance & Controlling Department	13.3yrs	keine Daten	keine Daten
Gabriele Ricci	Chief Data & Technology Officer	4.4yrs	keine Daten	0.0025% $ 1.3m
Christopher David O'Reilly	Global Head of Investor Relations & Global Finance	5.8yrs	keine Daten	keine Daten
Natalie Furney	Global General Counsel	1.3yrs	keine Daten	keine Daten

3.3yrs

Durchschnittliche Betriebszugehörigkeit

51yo

Durchschnittliches Alter

Erfahrenes Management: TKPH.FDas Führungsteam des Unternehmens gilt als erfahren (3.3 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Milano Furuta	CFO & Director	2.1yrs	JP¥384.00m	0.0019% $ 1.0m
Andrew S. Plump	President of Research & Development and Representative Director	11.1yrs	JP¥1.26b	0.020% $ 10.4m
So-Young Kim	CEO, President & Director	less than a year	keine Daten	0.0055% $ 2.9m
John Michael Maraganore	Independent External Director	4.1yrs	JP¥44.00m	0.00024% $ 125.9k
Steven S. Gillis	Independent External Director	7.5yrs	JP¥53.00m	0.00050% $ 262.3k
Paulus Stoffels	Independent External Director	less than a year	keine Daten	keine Daten
Bruce Broussard	Independent External Director	less than a year	keine Daten	0.000030% $ 15.7k
Miki Tsusaka	Independent External Director	3.1yrs	JP¥38.00m	keine Daten
Masami Iijima	Independent External Chair	5.1yrs	JP¥43.00m	0.00041% $ 215.1k
Kimberly A. Reed	Independent External Director	4.1yrs	JP¥47.00m	0.00028% $ 146.9k
Koichiro Kimura	Independent External Director	less than a year	keine Daten	keine Daten

3.1yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter

Erfahrener Vorstand: TKPH.FDie Vorstandsmitglieder gelten als erfahren (3.1 Jahre durchschnittliche Amtszeit).

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/07/06 20:39
Aktienkurs zum Tagesende	2026/07/02 00:00
Gewinne	2026/03/31
Jährliche Einnahmen	2026/03/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Takeda Pharmaceutical Company Limited wird von 27 Analysten beobachtet. 15 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Atsushi Seki	Barclays
Miki Sogi	Bernstein
Koichi Mamegano	BofA Global Research

Takeda Pharmaceutical Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Takeda Pharmaceutical Company Limited Announces Management and Committee Changes

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 24, 2026

Takeda Pharmaceutical Company Limited Announces Board and Executive Retirements

Takeda Announces Executive Changes, Effective June 2026

Takeda Pharmaceutical Company Limited Announces Change in Compensation Committee Members, Effective June 25, 2025

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 25, 2025

Recent updates

Takeda Pharmaceutical Company Limited Announces Management and Committee Changes

Takeda Pharmaceutical Company Limited Presents Additional Results from Two Pivotal Studies Showing Oveporexton Improves Daily Function, Cognition, and Nighttime Sleep for People with Narcolepsy Type 1

Takeda Announces Positive Topline Results for Phase 3 Study Comparing Zasocitinib to Deucravacitinib in Adults with Moderate-To-Severe Plaque Psoriasis

Takeda Pharmaceutical Company Limited to Report Q2, 2027 Results on Oct 29, 2026

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 24, 2026

Takeda Pharmaceutical Company Limited Announces Positive Topline Results From Pivotal Phase 2/3 Clinical Trial Of TAK-881 In Primary Immunodeficiency Disease

Takeda Pharmaceutical Company Limited Announces Zasocitinib Delivers Rapid and Durable Skin Clearance in Plaque Psoriasis

Takeda Pharmaceutical Company Limited Announces Board and Executive Retirements

Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Company Announce National Third-Party Payor Class Certified in Lawsuit Regarding Actos

Takeda Pharmaceutical Company Limited to Report Q1, 2027 Results on Jul 30, 2026

Takeda and Protagonist Therapeutics, Inc Announce FDA Accepts Priority Review for First-In-Class Therapy Rusfertide in Polycythemia Vera

Takeda Announces Positive Phase 3 Data Demonstrate Potential for ENTYVIO®? (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda Pharmaceutical Company Limited's Oveporexton (TAK-861) as A Potential First-In-Class Therapy for Narcolepsy Type 1

Takeda Pharmaceutical Company Limited Revises Consolidated Earnings Guidance for the Fiscal Year 2025

Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-To-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content

Takeda and Protagonist Announce Submission of New Drug Application for Rusfertide for Treatment of Polycythemia Vera

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Takeda Pharmaceutical Company Limited to Report Q3, 2026 Results on Jan 29, 2026

Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Present Longer-Term Data At ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

Wisner Baum Unleashes Rico Against Takeda Pharmaceuticals and Eli Lilly

Takeda Presents New Data Showing Mezagitamab Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy

Takeda Inc. Announces Completion of the 7-Year Pivotal Phase 3 Tides Trial Evaluating Its Dengue Vaccine, Qdenga®?V

Takeda Pharmaceutical Company Limited Declares Dividend for Second Quarter-End of Fiscal Year Ending March 31, 2026, Payable on December 1, 2025

Takeda Inc. Announces the Recently FDA- Approved Hyhub and Hyhub Duo Devices Now Available in the U.S. to Simplify Hyqvia® Infusion Preparation

Takeda Announces Executive Changes, Effective June 2026

Takeda Presents Orexin Data from Landmark Oveporexton Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

Takeda Announces U.S. FDA Approves Expanded Indication for VONVENDI for Adults and Children with Von Willebrand Disease

Takeda Pharmaceutical Company Limited to Report Q2, 2026 Results on Oct 30, 2025

Takeda Pharmaceutical Company Limited Announces an Embargoed Version of an Abstract for Phase 3 TAK-861-3002 Study (Radiantlight) of Oveporexton (TAK-861) in Narcolepsy Type 1, Which Is Slated to Be Presented At the Upcoming World Sleep 2025 Congress

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Fiscal Year 2025

Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHub Duo Devices to Simplify HYQVIA Administration

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (Tak-861) in Narcolepsy Type 1

Takeda Pharmaceutical Company Limited Approves Dividend

Takeda Pharmaceutical Company Limited Announces U.S. FDA Approval of Gammard Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content

Takeda Pharmaceutical Company Limited Announces Change in Compensation Committee Members, Effective June 25, 2025

Ninth Circuit Affirms Actos RICO Class Action Certification Against Takeda and Eli Lilly

European Commission Approves Adcetris®? (Brentuximab Vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage Iib/Iii/Iv Hodgkin Lymphoma in Combination with Ecadd

Protagonist Therapeutics, Inc. and Takeda Announce Asco Plenary Presentation Highlighting Full 32-Week Results from Phase 3 Verify Study of Rusfertide

Takeda Announces The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 25, 2025

Takeda Pharmaceutical Company Limited Receives Approval by the Japanese Ministry of Health, Labour, and Welfare for Livmarli®? (Maralixibat) Oral Solution for the Treatment of Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis in Japan

Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Announces Positive Topline Results from Phase 3 Verify Study of Rusfertide in Patients with Polycythemia Vera

Takeda Pharmaceutical Company Limited to Report Q1, 2026 Results on Jul 30, 2025

Takeda Pharmaceutical Company Limited (TSE:4502) announces an Equity Buyback for 28,500,000 shares, representing 1.8% for ¥100,000 million.

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Pharmaceutical Company Limited to Report Q3, 2025 Results on Jan 30, 2025

Takeda Pharmaceutical Company Limited Raises Earnings Guidance for the Full Year 2024

Takeda Receives Approval from the Japanese Ministry of Health, Labour and Welfare to Manufacture and Market Fruquintinib for Previously Treated Colorectal Cancer

Takeda Receives European Commission Approval for ADZYNMA®

Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)

Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

FDA Approves Takeda's EOHILIA (budesonide Oral Suspension)

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda's Gammard Liquidid®? Approves by U.S. Fda for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Takeda Announces U.S. Food and Drug Administration Approves Hyqvia® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]